Kodiak reports positive Phase 3 results
Zenkuda and tabirafusp-ted met primary endpoints for wet AMD, showing durable dosing intervals compared to aflibercept. Experts praise the unique clinical profile. The team thanks participants.
Latest Kodiak Sciences News & Updates
See the latest news and media coverage for Kodiak. We track all announcements, press releases, and industry mentions in real time, all in one place.
Retina-focused biotechnology company
kodiak.com- Headquarters
- Palo Alto, United States
- Founded year
- 2009
- Company type
- Public company
- Number of employees
- 125–200
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about Kodiak Sciences (Kodiak)
In short: Kodiak reported Q2 2026 results and scheduled DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in wet AMD for September 28, 2026.
Company announcements
Kodiak completes first cohort enrollment for KSI-101 MESI trial
The Phase 3 PEAK trial enrolled 300 patients. Topline data release remains scheduled for December 2026.
Kodiak announces positive GLOW2 Phase 3 results for Zenkuda in diabetic retinopathy
Zenkuda demonstrated superiority to sham with 62.5% efficacy and improved safety. Kodiak plans to accelerate its BLA submission timeline based on these robust clinical outcomes.
Kodiak presents Phase 1b APEX study results for KSI-101
Dr. Sumit Sharma shares positive MESI clinical data at Angiogenesis meeting, supporting efficacy and safety ahead of Phase 3 trials.
Media coverage
KOD Maintained by UBS -- Price Target Raised to $120
Kodiak Sciences (KOD) Analyst Rating Update On October 03, 2023, UBS has maintained its "Buy" rating for Kodiak Sciences (KOD) while raising the price...
Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron s
Shares of Kodiak Sciences surged more than 170% Monday—on pace for its largest one-day increase on r...
Upcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD)
Kodiak Sciences recently highlighted that it is on track to report top-line Phase III DAYBREAK results for Zenkuda (tarcocimab tedromer) and KSI-501 in treatment-naïve wet...
Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases
Nona Biosciences partners with Kodiak Sciences to advance discovery of novel multi-target antibodies for ophthalmic diseases.
Never miss news about Kodiak
Track Kodiak and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Kodiak competitors & trending companies
Browse news for competitors to Kodiak and other trending companies.